Advances in the management of hyperkalemia in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 26, Issue 3, 2017, Pages 235-239

  Cowan, Andrea C J ^a   Gharib, Elie G ^a   Weir, Matthew A ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Chronic kidney disease; hyperkalemia; Patiromer; Sodium zirconium cyclosilicate

Indexed keywords

ION EXCHANGE RESIN; PATIROMER; POTASSIUM; SODIUM ZIRCONIUM CYCLOSILICATE; POLYMER; SILICATE; ZS-9 COMPOUND;

CHRONIC KIDNEY FAILURE; FOLLOW UP; HUMAN; HYPERKALEMIA; OUTPATIENT; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; POTASSIUM RESTRICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADMINISTRATION AND DOSAGE; COMPLICATION; POTASSIUM INTAKE; URINE;

HUMANS; HYPERKALEMIA; ION EXCHANGE RESINS; POLYMERS; POTASSIUM; POTASSIUM, DIETARY; RENAL INSUFFICIENCY, CHRONIC; SILICATES;

EID: 85013080318     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000320     Document Type: Review

References (37)

1. Moranne O, Froissart M, Rossert J, et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 2009; 20:164-171.
2. Fleet JL, Shariff SZ, Gandhi S, et al. Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission. BMJ Open 2012; 2:e002011.
3. Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol 2012; 7:1234-1241.
4. Musso CG. Potassium metabolism in patients with chronic kidney disease (CKD), Part I: patients not on dialysis (stages 3-4). Int Urol Nephrol 2004; 36:465-468.
5. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009; 169:1156-1162.
6. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 2014; 34:333-339.
7. Remuzzi G, Perico N,Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005; 68:S57-65.
8. Korgaonkar S, Tilea A, Gillespie BW, et al. Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol 2010; 5:762-769.
9. Jain N, Kotla S, Little BB, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012; 109:1510-1513.
10. Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther 2012; 30:e156-e166.
11. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70:2116-2123.
12. Chen Y, Chang AR, McAdams DeMarco MA, et al. Serum potassium, mortality, and kidney outcomes in the Atherosclerosis Risk in Communities Study. Mayo Clin Proc 2016; 91:1403-1412.
13. Hayes J, Kalantar-Zadeh K, Lu JL, et al. Association of hypo-and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract 2012; 120:c8-c16.
14. Blumberg A, Weidmann P, Ferrari P. Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. Kidney Int 1992; 41:369-374.
15. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4:542-551.
16. Goraya N, Wesson DE. Dietary management of chronic kidney disease: protein restriction and beyond. Curr Opin Nephrol Hypertens 2012; 21:635-640.
17. National Kidney Foundation. Potassium and your CKD diet. New York: National Kidney Foundation; 2016; Available from: https://www.kidney.org/ atoz/content/potassium. [Cited 25 November 2016]
18. Ray K, Dorman S, Watson R. Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction. J Hum Hypertens 1999; 13:717-720.
19. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998; 158:2200-2211.
20. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351:585-592.
21. Perazella MA. Trimethoprim-induced hyperkalaemia: clinical data, mechanism, prevention and management. Drug Saf 2000; 22:227-236.
22. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000; 109:307-314.
23. Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. J Am Soc Nephrol 1998; 9:1535-1543.
24. Kessler C, Ng J, Valdez K, et al. The use of sodium polystyrene sulfonate in the inpatient management of hyperkalemia. J Hosp Med 2011; 6:136-140.
25. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 2010; 21:733-735.
26. Scherr L, Ogden DA, Mead AW, et al. Management of hyperkalemia with a cation-exchange resin. N Engl J Med 1961; 264:115-119.
27. Flinn RB, Merrill JP, Welzant WR. Treatment of the oliguric patient with a new sodium-exchange resin and sorbitol; a preliminary report. N Engl J Med 1961; 264:111-115.
28. Gruy-Kapral C, Emmett M, Santa Ana CA, et al. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with endstage renal disease. J Am Soc Nephrol 1998; 9:1924-1930.
29. Watson M, Abbott KC, Yuan CM. Damned if you do, damned if you don't: potassium binding resins in hyperkalemia. Clin J Am Soc Nephrol 2010; 5:1723-1726.
30. Gerstman BB, Kirkman R, Platt R. Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. YAJKD 1992; 20:159-161.
31. McGowan CE, Saha S, Chu G, et al. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J 2009; 102:493-497.
32. Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011; 32:820-828.
33. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYSTDN randomized clinical trial. JAMA 2015; 314:151-161.
34. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015; 372:211-221.
35. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014; 312:2223-2233.
36. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015; 372:222-231.
37. AstraZeneca receives Complete Response Letter from US FDA for sodium zirconium cyclosilicate (ZS-9) for oral suspension for treatment of hyperkalemia. [Internet]. astrazeneca.com. 2016; [cited 15 November 2016]. Available from: https://www.astrazeneca.com/media-centre/press-releases/ 2016/astrazeneca-receives-complete-response-letter-from-us-fda-for-sodiumzirconium-cyclosilicate-zs-9-for-oral-suspension-for-treatment-of-hyperkalaemia-27052016.html.